After winning key support for Celgene buyout, Bristol-Myers CEO Caforio emerges as clear likely winner in looming shareholder vote

It’s likely all over but for the shareholder vote and regulatory approvals now.

After Bristol-Myers Squibb’s largest shareholder startled Wall Street with its outright opposition to the big Celgene buyout, the activists at Starboard Value helped make it interesting with their own intense — but short-lived — campaign to squelch the deal.